CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.67M | -18.25M | -26.51M | -14.23M | -154.00K |
| Total Depreciation and Amortization | 47.00K | 251.00K | 510.00K | 134.00K | 347.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.51M | 5.11M | 2.32M | 1.88M | 2.14M |
| Change in Net Operating Assets | 37.00K | -12.66M | 434.00K | -3.33M | -18.09M |
| Cash from Operations | -18.07M | -25.55M | -23.24M | -15.55M | -15.75M |
| Capital Expenditure | -- | -- | -201.00K | 127.00K | -27.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.95M | -192.78M | -14.22M | 312.00K | -76.33M |
| Cash from Investing | 5.95M | -192.78M | -14.42M | 439.00K | -76.36M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 511.00K | 228.63M | 16.64M | 253.00K | 93.55M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 5.86M | -- | -- | -- |
| Cash from Financing | 511.00K | 234.49M | 16.64M | 253.00K | 93.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.60M | 16.16M | -21.02M | -14.86M | 1.44M |